← Browse by Condition
Medical Condition
advanced or metastatic solid tumors
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 1, Phase 1, Phase 2
NCT05787587 Phase 1
Recruiting
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Enrollment
216 pts
Location
United States
Sponsor
IDEAYA Biosciences
NCT05785754 Phase 1
Recruiting
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Enrollment
320 pts
Location
United States, Austr...
Sponsor
DynamiCure Biotechnology
NCT06395519 Phase 1, Phase 2
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Enrollment
120 pts
Location
United States
Sponsor
858 Therapeutics, Inc.
NCT06781983 Phase 1
Recruiting
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Enrollment
145 pts
Location
United States, Franc...
Sponsor
Innate Pharma
NCT06374173 Phase 1
Recruiting
A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors
Enrollment
123 pts
Location
China
Sponsor
Hefei TG ImmunoPharma Co., Ltd...
NCT06196762 Phase 1
Recruiting
Phase I of XKH002 Injection in Patients
Enrollment
110 pts
Location
China
Sponsor
Zhejiang Kanova Biopharmaceuti...